(Reuters) — Bayer AG faced a second American jury Feb. 25 over allegations that its popular glyphosate-based weed killer Roundup causes cancer.
The trial comes six months after the company’s share price was rocked by a US$289 million verdict in California state court.
The lawsuit by California resident Edwin Hardeman against the company began in federal rather than state court. The trial is also a test case for a larger litigation. More than 760 of the 9,300 Roundup cases nationwide are consolidated in the federal court in San Francisco that is hearing Hardeman’s case.
Bayer denies all allegations that Roundup or glyphosate cause cancer, specifically non-Hodgkin’s lymphoma, saying decades of independent studies have shown the world’s most widely used weed killer to be safe for human use and noting that regulators around the world have approved the product.
During the first phase in the trial, the nine-person jury is asked to weigh scientific evidence to determine whether Roundup caused Hardeman’s lymphoma.
Aimee Wagstaff, a lawyer for Hardeman, told a packed courtroom during her opening statement that chemicals in Roundup made the weed killer more toxic than glyphosate alone, causing the man’s cancer.
But U.S. District Judge Vince Chhabria, who presides over the federal litigation, repeatedly scolded her for “crossing the line” by referring to internal corporate communications the judge has said have no bearing on the science in the case.
“You completely disregarded the limitations,” Chhabria said.
In a January ruling, Chhabria called evidence by plaintiffs that the company allegedly attempted to influence regulators and manipulate public opinion “a distraction” from the scientific question of whether glyphosate causes cancer.
If the jury determines Roundup caused Hardeman’s cancer, the judge said such evidence could be presented in a second trial phase.
Plaintiffs criticized Chhabria’s order dividing the trial and restricting evidence as “unfair,” saying their scientific evidence allegedly showing glyphosate causes cancer is inextricably linked to Monsanto’s alleged wrongful conduct.
Evidence of corporate misconduct was seen as playing a key role in the finding by a California state court jury in August that Roundup caused another man’s non-Hodgkin’s lymphoma and that Bayer’s Monsanto unit failed to warn consumers about the weed killer’s cancer risks. That jury’s $289 million damages award was later reduced to $78 million.
Bayer’s share price dropped 10 percent following the verdict and has remained volatile.
Brian Stekloff, a lawyer for Bayer, in his opening statement attacked the idea of a link between Roundup and cancer. He noted U.S. rates of non-Hodgkin’s lymphoma have remained steady over time, even when Roundup use began to soar in the 1990s.
Hardeman began using the Roundup brand herbicide with glyphosate in the 1980s to control poison oak and weeds on his property and sprayed “large volumes” of the chemical for many years on a regular basis, according to court documents. He was diagnosed with non-Hodgkin’s lymphoma at the age of 66 in February 2015 and filed his lawsuit a year later. Hardeman is currently in remission.
But Stekloff said during the new trial Feb. 25 that Hardeman’s age and his history of chronic hepatitis C were known risk factors for developing lymphoma. The lawyer also said the majority of non-Hodgkin’s lymphoma incidents are idiopathic, or have no known cause.